In vitro selection of fluorogenic RNA-cleaving DNAzymes for colorectal cancer detection

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, accounting for over 600,000 deaths annually. The mortality rate of CRC can be significantly reduced if it is detected early, suggesting the importance of cancer screening in CRC management. Currently, colonoscopy is the gold standard for CRC diagnosis as it is accurate and reliable. However, it is an invasive procedure that is associated with risks of complications, which contributes to the lack of patient compliance in colonoscopy screening. Other noninvasive detection methods suffer from poor sensitivity and specificity. Thus, there remains a great demand for the development of a noninvasive and accurate test for CRC diagnosis. Recently, studies using next-generation sequencing techniques have revealed compositional changes in the intestinal microbiome associated with CRC, implicating the possibility of using fecal microbiome as potential diagnostic markers. Specifically, the level of the gram-negative bacterium, Fusobacterium nucleatum, has been shown to be elevated in CRC patients compared to healthy controls. The work described in this thesis aims to develop unique RNA-cleaving DNAzymes that can distinguish between healthy and CRC stool microbiomes. RNA-cleaving DNAzymes are single stranded DNA molecules that are extensively used as analytical tools for metal ion sensing and bacterial detection. We conducted an in vitro selection experiment and isolated a F. nucleatum-responsive RNA-cleaving DNAzyme sensor, named RFD-FN1, that is activated by a heat stable protein marker by this bacterium. RFD-FN1 is highly specific for F. nucleatum and it has a limit of detection of 107 CFU/mL without culture and a single cell when cultured for 36 hours. The discovery of this novel molecular probe for F. nucleatum presents an important step forward towards the development of a novel DNAzyme-based detection method for colorectal cancer.